Urine cyclic adenosine monophosphate (cAMP) is a biomarker to assess the residual function of the collecting duct in the kidney. Prognostic implication of urine cAMP levels in patients with chronic kidney disease (CKD) remains unknown. Patients who were followed at our specific outpatient clinic to treat their CKD between December 2015 and December 2019 were included in this prospective study. The impact of urine cAMP levels on the composite of dialysis administration, cardiovascular death, and doubling of serum creatinine concentration was investigated. A total of 106 patients (median 72years old, 80 men, and median estimated glomerular filtration rate 28.4mL/min/1.73 m2) were included. Urine cAMP levels ranged widely between 0.35 and 4.08nmol/mg of creatinine with a median value of 1.99nmol/mg of creatinine. A urine cAMP level was an independent predictor of the primary endpoint with a hazard ratio of 0.41 (95% confidence interval 0.18-0.91, p = 0.029) adjusted for 5 potential confounders with a cutoff of 1.55nmol/mg of creatinine. A lower urine cAMP is an independent predictor of renal deterioration and cardiovascular death in patients with CKD.